BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 18677012)

  • 21. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.
    Filocamo G; Buoncompagni A; Viola S; Loy A; Malattia C; Ravelli A; Martini A
    J Pediatr; 2008 Sep; 153(3):432-4. PubMed ID: 18718263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
    Mohan AK; Coté TR; Block JA; Manadan AM; Siegel JN; Braun MM
    Clin Infect Dis; 2004 Aug; 39(3):295-9. PubMed ID: 15306993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-TNF alpha agents in vasculitis].
    Solans Laqué R; Bosch Gil JA
    Med Clin (Barc); 2008 Feb; 130(3):93-4. PubMed ID: 18261379
    [No Abstract]   [Full Text] [Related]  

  • 27. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
    Pontikaki I; Gerloni V; Gattinara M; Luriati A; Salmaso A; De Marco G; Teruzzi B; Valcamonica E; Fantini F
    Reumatismo; 2006; 58(1):31-8. PubMed ID: 16639486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.
    Efthimiou P; Schwartzman S; Kagen LJ
    Ann Rheum Dis; 2006 Sep; 65(9):1233-6. PubMed ID: 16476710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.
    Buch MH; Bingham SJ; Bryer D; Emery P
    Rheumatology (Oxford); 2007 Jul; 46(7):1153-6. PubMed ID: 17478470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
    Haitz KA; Kalb RE
    J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series.
    Garcovich S; Di Giampetruzzi AR; Antonelli G; Garcovich A; Didona B
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):881-4. PubMed ID: 20002243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
    Josselin L; Mahr A; Cohen P; Pagnoux C; Guaydier-Souquières G; Hayem G; Job-Deslandre C; Liferman F; Pourrat J; Guillevin L
    Ann Rheum Dis; 2008 Sep; 67(9):1343-6. PubMed ID: 18445626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
    Lozeron P; Denier C; Lacroix C; Adams D
    Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
    Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
    Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.